记录 cT3-4M0 喉内鳞状细胞癌 (SCC) 患者初次全喉切除术 (TL) 的 10 年肿瘤学结果。使用 STROBE 指南对 40 年来 531 名孤立的未经治疗的喉内 cT3-4M0 SCC 患者进行观察性初始队列回顾。 94% 的患者被随访直至死亡或至少 10 年。学术三级转诊护理中心。所有患者均接受初级 TL。既往气管切开术、诱导化疗、甲状腺切除、II-IV 级颈清扫术、VI 级清扫术和术后放射治疗分别与 6%、40%、43%、89%、47% 和 74% 的病例相关：主要目标是确定 10 年精算本地控制估计。辅助目标包括筛查增加局部复发风险的临床变量，以及分析局部复发的长期肿瘤学后果。10 年精算局部控制估计值为 89.7%。 11% 的病例局部复发得到挽救，总体局部控制率为 92%。在多变量分析中，没有一个研究变量与局部复发相关。局部复发导致淋巴结控制、远处转移控制和生存率显着降低。在 TL 后 10 年期间记录的 334 例死亡中，术后并发症、持续指数 SCC、并发疾病和异时第二原发癌分别占 3%、37%、33% 和 28%。原发性 TL 的肿瘤学疗效、局部复发的危险、局部控制对生存的关键作用以及长期肿瘤观察政策的重要性。3 喉镜，2023 年。© 2023 作者。 《喉镜》由 Wiley periodicals LLC 代表美国喉科、鼻科和耳科协会出版。

To document 10-year oncologic outcome of primary total laryngectomy (TL) for patients with cT3-4M0 endolaryngeal squamous cell carcinoma (SCC).Observational inception cohort of 531 patients with isolated untreated endolaryngeal cT3-4M0 SCC review over 40 years using STROBE guideline. 94% of patients were followed until death or for a minimum of 10 years.Academic tertiary referral care center.All patients underwent primary TL. Prior tracheotomy, induction chemotherapy, thyroid gland resection, level II-IV neck dissection, level VI dissection, and postoperative radiation therapy were associated in 6%, 40%, 43%, 89%, 47%, and 74% of cases, respectively: The main objective was to determine the 10-year actuarial local control estimate. Accessory objectives comprised screening for clinical variables increasing the risk of local recurrence, and analysis of long-term oncologic consequences of local recurrence.The 10-year actuarial local control estimate was 89.7%. Local recurrence was salvaged in 11% of cases, resulting in 92% overall local control. On multivariate analysis, none of the study variables correlated with local recurrence. Local recurrence resulted in significantly reduced nodal control, distant metastasis control, and survival. Postoperative complications, persistent index SCC, intercurrent disease, and metachronous second primary cancer accounted for respectively 3%, 37%, 33%, and 28% of the 334 deaths noted during the 10 years following TL.The present study underscored the long-term oncologic efficacy of primary TL, the dangers of local recurrence, the key role of local control for survival, and the importance of a long-term oncologic watch policy.3 Laryngoscope, 2023.© 2023 The Authors. The Laryngoscope published by Wiley Periodicals LLC on behalf of The American Laryngological, Rhinological and Otological Society, Inc.